SSTR2 and breast cancer: The aim of this study was to compare a potent antagonist, 68Ga-NODAGA-JR11, and two commonly used agonists, 68Ga-DOTATATE and 68Ga-DOTATOC, for in vivo breast cancer imaging using a human xenograft model with endogenous sstr2 expression.